Charles S. Cleeland

Charles S. Cleeland

Auto-generated profile, based on publicly available information

Charles S. Cleeland

Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Cancer
Verified
Journal Article
Closed access
PDF file
CCCharles S. Cleeland
Charles S. Cleeland
TMTito R. Mendoza
Tito R. Mendoza
XWXin Shelley Wang
Xin Shelley Wang
CCChyi Chou
Chyi Chou
MHMargaret T. Harle
Margaret T. Harle
MEMartha C. Engstrom
Martha C. Engstrom

1 November 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
ADAmylou C. Dueck
Amylou C. Dueck
TMTito R. Mendoza
Tito R. Mendoza
SMSandra A Mitchell
Sandra A Mitchell
BRBryce B Reeve
Bryce B Reeve
KCKathleen M. Castro
Kathleen M. Castro
FGfor the National Cancer Institute PRO-CTCAE Study Group
for the National Cancer Institute PRO-CTCAE Study Group
In cancer clinical trials, adverse events (AEs) are collected and reported using the US National Cancer Institute’s (NCI’s) Common Terminology Criteria for Adverse Events (CTCAE).1 The CTCAE is a library of items representing 790 discrete AEs, each graded using an ordinal severity scale.2 Approximately 10% of AEs in the CTCAE are symptoms (eg, nausea, sensory neuropathy), which in trials have historically been reported by clinical investigators.3 However, there is empirical evidence that collection of this information directly from patients improves the precision and reliability of symptomatic AE detection in trials4-9and is feasible.10,11 Moreover, there is substantial evidence that clinical investigators may miss up to half of patients’ symptomatic AEs.5,6,12,13

19 May 2003 in Cancer
Verified
Journal Article
Open access
PDF file
CCCharles S. Cleeland
Charles S. Cleeland
GBGary J. Bennett
Gary J. Bennett
RDRobert Dantzer
Robert Dantzer
PDPatrick M. Dougherty
Patrick M. Dougherty
ADAdrian J. Dunn
Adrian J. Dunn
BLBang‐Ning Lee
Bang‐Ning Lee
BACKGROUND: Cancers and cancer treatments produce multiple symptoms that collectively cause a symptom burden for patients. These symptoms include pain, wasting, fatigue, cognitive impairment, anxiety, and depression, many of which co‐occur. There is growing recognition that at least some of these symptoms may share common biologic mechanisms.METHODS: In November 2001, basic and clinical scientists met to consider evidence for a cytokine‐immunologic model of symptom expression along with directions for future research.RESULTS: The characteristics of cytokine‐induced sickness behavior in animal models have much in common with those of symptomatic cancer patients. Sickness behavior refers to a set of physiologic and behavioral responses observed in animals after the administration of infectious or inflammatory agents or certain proinflammatory cytokines. In some cases, these responses can be prevented by cytokine antagonists. A combination of animal and human research suggests that several cancer‐related symptoms may involve the actions of proinflammatory cytokines.CONCLUSIONS: Based on the similarities between cancer symptoms and sickness behavior, the authors discussed approaches to further test the implications of the relationship between inflammatory cytokines and symptoms for both symptom treatment and symptom prevention. Cancer 2003;97:2919–25. © 2003 American Cancer Society.DOI 10.1002/cncr.11382

1 October 2007 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
CCCharles S. Cleeland
Charles S. Cleeland
Cancer and its treatment produce multiple symptoms that significantly distress patients and impair function. Symptoms caused by treatment may delay treatment or lead to premature treatment termination, and residual treatment-related symptoms often complicate posttreatment rehabilitation. When treatment is no longer possible, symptom control becomes the focus of cancer care. Patient ratings of symptom severity and impact are important patient-reported outcomes (PROs) in cancer clinical trials and comprise a subset of a larger domain of PROs generally referred to as health-related quality of life (HRQOL). Symptoms rarely occur in isolation; rather, there is now ample evidence that symptoms frequently occur in clusters. The impact of these multiple symptoms upon the patient can be described as “symptom burden,” a concept that encompasses both the severity of the symptoms and the patient's perception of the impact of the symptoms. The distress caused by symptoms is a subject of much investigation, and several validated measures of the severity and impact of multiple symptoms are now available. Symptom measures are generally brief, thereby reducing respondent burden, and can be administered repeatedly during a trial to give a relatively fine-grained picture of the patient's status across time. In many instances, information on trial-related changes in symptom burden, or comparison of symptom burden between arms in a clinical trial, may provide sufficient self-report data for clinical trial consumers (patients, clinicians, and regulators) to make treatment choices or to evaluate new therapies, without measuring other HRQOL domains.

10 March 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CCCharles S. Cleeland
Charles S. Cleeland
XWXin Shelley Wang
Xin Shelley Wang
QSQiuling Shi
Qiuling Shi
TMTito R. Mendoza
Tito R. Mendoza
SWSherry L. Wright
Sherry L. Wright
AVAra A. Vaporciyan
Ara A. Vaporciyan
Purpose: Patients receiving cancer-related thoracotomy are highly symptomatic in the first weeks after surgery. This study examined whether at-home symptom monitoring plus feedback to clinicians about severe symptoms contributes to more effective postoperative symptom control. Patients and Methods: We enrolled 100 patients receiving thoracotomy for lung cancer or lung metastasis in a two-arm randomized controlled trial; 79 patients completed the study. After hospital discharge, patients rated symptoms twice weekly for 4 weeks via automated telephone calls. For intervention group patients, an e-mail alert was forwarded to the patient's clinical team for response if any of a subset of symptoms (pain, disturbed sleep, distress, shortness of breath, or constipation) reached a predetermined severity threshold. No alerts were generated for controls. Group differences in symptom threshold events were examined by generalized estimating equation modeling. Results: The intervention group experienced greater reduction in symptom threshold events than did controls (19% v 8%, respectively) and a more rapid decline in symptom threshold events. The difference in average reduction in symptom interference between groups was −0.36 (SE, 0.078; P = .02). Clinicians responded to 84% of e-mail alerts. Both groups reported equally high satisfaction with the automated system and with postoperative symptom control. Conclusion: Frequent symptom monitoring with alerts to clinicians when symptoms became moderate or severe reduced symptom severity during the 4 weeks after thoracic surgery. Methods of automated symptom monitoring and triage may improve symptom control after major cancer surgery. These results should be confirmed in a larger study.

24 September 2013 in Cancer
Verified
Journal Article
Open access
PDF file
CCCharles S. Cleeland
Charles S. Cleeland
FZFengmin Zhao
Fengmin Zhao
VCVictor T. Chang
Victor T. Chang
JSJeff A. Sloan
Jeff A. Sloan
AOAnn M. O'Mara
Ann M. O'Mara
MFMichael J. Fisch
Michael J. Fisch
BACKGROUND: A set of common cancer‐related and treatment‐related symptoms has been proposed for quality of care assessment and clinical research. Using data from a large, multicenter, prospective study, the authors assessed the effects of disease site and stage on the percentages of patients rating these proposed symptoms as moderate to severe.METHODS: The severity of 13 symptoms proposed to represent “core” oncology symptoms was rated by 3106 ambulatory patients with cancer of the breast, prostate, colon/rectum, or lung, regardless of disease stage or phase of care; 2801 patients (90%) repeated the assessment 4 to 5 weeks later.RESULTS: At the time of the initial assessment, approximately 33% of the patients reported ≥ 3 symptoms in the moderate‐to‐severe range; 11 of the 13 symptoms were rated as moderate to severe by at least 10% of all patients and 6 were rated as moderate to severe by at least 20% of those receiving active treatment. Fatigue/tiredness was the most severe symptom, followed by disturbed sleep, pain, dry mouth, and numbness/tingling. More patients with lung cancer and patients receiving active treatment reported moderate to severe symptoms. Percentages of symptomatic patients increased by disease stage, less adequate response to therapy, and declining Eastern Cooperative Oncology Group performance status. The percentages of patients reporting moderate to severe symptoms were stable across both assessments.CONCLUSIONS: The results of the current study support a core set of moderate to severe symptoms that are common across outpatients with solid tumors, that can guide consideration of progression‐free survival as a trial outcome, and that should be considered in clinical care and in assessments of quality of care and treatment benefit. Cancer 2013;119:4333–4340. © 2013 American Cancer Society.